Inventiva S.A. (NASDAQ:IVA) Receives $17.00 Average Target Price from Analysts

Inventiva S.A. (NASDAQ:IVA) has received an average rating of “Buy” from the seven brokerages that are currently covering the firm, MarketBeat reports. Seven analysts have rated the stock with a buy rating. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $17.00.

Several equities research analysts have recently weighed in on IVA shares. Canaccord Genuity Group boosted their target price on shares of Inventiva from $12.00 to $20.00 and gave the stock a “buy” rating in a research report on Monday, April 8th. HC Wainwright reissued a “buy” rating and issued a $22.00 price objective on shares of Inventiva in a report on Monday, April 1st.

Institutional Trading of Inventiva

A hedge fund recently bought a new stake in Inventiva stock. Virtu Financial LLC bought a new stake in Inventiva S.A. (NASDAQ:IVA) during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm bought 10,490 shares of the company’s stock, valued at approximately $38,000. 19.06% of the stock is currently owned by hedge funds and other institutional investors.

Inventiva Stock Performance

Shares of NASDAQ:IVA opened at $2.95 on Wednesday. The company has a fifty day simple moving average of $3.30 and a 200 day simple moving average of $3.66. Inventiva has a 12-month low of $2.52 and a 12-month high of $4.75.

Inventiva Company Profile

Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI.